Delivery Order SPE2DB20D1100-SPE2DB25FB9H9
- Not listed
- The Defense Logistics Agency awarded a $23,799.46 delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (60 count) on May 8, 2025, with completion scheduled for May 9, 2025. This firm fixed-price contract, which was competitively awarded with no set-aside designation, will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Restasis is a prescription ophthalmic medication used to treat dry eye disease, representing part of...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on November 8, 2024, for the supply of Restasis 0.05% Eye Emulsion (60-count units) with a ceiling value of $2,822.04. This is a firm fixed-price delivery order with an ultimate completion date of November 12, 2024, and represents a competitively awarded contract with no set-aside designation. The award was made to AmerisourceBergen's Corporate Office division, headquartered in...
- The Defense Logistics Agency awarded a $3,561.92 delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (30-count) on September 12, 2025, with an ultimate completion date of September 15, 2025. This competitive award, issued under firm fixed-price terms with no set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply...
- The Defense Logistics Agency awarded a $3,018.16 delivery order to AmerisourceBergen Drug Corp for RESTASIS 0.05% Eye Emulsion (30-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $2,169.08 delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (30-count units) on June 2, 2025, with an ultimate completion date of June 3, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Restasis 0.05% eye emulsion in 60-count packaging, with a contract ceiling value of $2,658.60. This is a firm fixed-price delivery order with no set-aside designation, utilizing competitive procurement procedures. The order is scheduled for completion by September 29, 2025, and will be fulfilled from the contractor's Conshohocken, Pennsylvania location, where...
- The Defense Logistics Agency awarded a delivery order valued at $14,980.58 to AmerisourceBergen Drug Corp for the supply of Restasis 0.05% Eye Emulsion (60-count units) on September 4, 2025, with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of the vendor's extensive pharmaceutical supply relationship with the federal government. The product will be delivered to...
- The Defense Logistics Agency awarded a $6,297.40 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Restasis 0.05% eye emulsion (60-unit package). This non-set-aside, competitively awarded contract features firm fixed pricing and is scheduled for completion by July 29, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's larger...
- The Defense Logistics Agency awarded a $1,117.68 delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% eye emulsion (60 count) on July 22, 2025, with an ultimate completion date of July 23, 2025. This firm fixed price delivery order represents a non-competitive set-aside contract and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency awarded a $12,777.96 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Restasis 0.05% Eye Emulsion in 60-count units. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive procurement. Performance will be completed by July 29, 2025, with work performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FB9H9Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% eye emulsion in a 30-count package on April 24, 2025, with a ceiling value of $1,221.73 and a completion date of April 25, 2025. This delivery order represents a firm fixed-price, non-set-aside contract executed as a child order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The vendor, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through competitive procurement processes. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at approximately $1 billion through December 2026. The IDC functions as a comprehensive global pharmaceutical support vehicle enabling the company to supply medications, vaccines, and medical supplies to support Defense Health Agency and other government healthcare systems worldwide. Restasis, an ophthalmologic emulsion used to treat dry eye disease, represents one of the specialized pharmaceutical products available under this extensive pharmaceutical prime vendor arrangement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 4/24/25 |